Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M

Nuvation Bio Inc.

Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.
Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.
Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.
MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.
Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026.

item 1.01 item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).

Action: entry
Agreement: license
Counterparty: Eisai Co., Ltd.
Value: €50 million
Effective: 2026-01-11

Exact text from the filing

On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-009826

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.